@article{fdi:010015515,
  title = {{T}he {S}enegal pertussis trial : safety and surveillance of adverse reactions},
  author = {{P}r{\'e}ziosi, {M}arie-{P}ierre and {N}diaye, {M}alick and {C}oll-{S}eck, {A}. and {S}imondon, {F}ran{\c{c}}ois},
  editor = {},
  language = {{ENG}},
  abstract = {{I}n the {S}enegal pertussis trial, common adverse reactions were actively monitored during the pilot phase {II} study, while the frequency of severe adverse reactions was monitored as a secondary objective within the phase {III} efficacy trial. {S}ince the trial was conducted in {N}iakhar, an area in rural {W}est {A}frica under intensive surveillance, the safety monitoring during the study was incorporated within the general surveillance system. {T}his was a two-step procedure : detection of a potential reaction by a field worker, followed by confirmation report by a physician. {T}he frequency of severe reactions was slow among both pertussis vaccine groups, receiving either the two-component acellular vaccine or the whole-cell vaccine, currently used in the {S}enegal {E}xpanded {P}rogramme on {I}mmunisation. {A}mong severe reactions, only persistent crying was found to be at a significantly higher rate in the whole-cell group. {C}ommon adverse reactions were more frequent in the whole-cell group. ({R}{\'e}sum{\'e} d'auteur)},
  keywords = {{VACCINATION} ; {TOLERANCE} ; {MORTALITE} {INFANTILE} ; {CHIMIOPROPHYLAXIE} {DE} {MASSE} ; {COQUELUCHE} ; {EFFET} {SECONDAIRE} ; {SENEGAL} ; {NIAKHAR} {REGION}},
  booktitle = {{P}ertussis vaccine trials},
  journal = {},
  volume = {89},
  numero = {},
  pages = {91--97},
  year = {1997},
  URL = {https://www.documentation.ird.fr/hor/fdi:010015515},
}